• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Interleukin-6 and interleukin-8 serum levels in prognosis of hormone- dependent breast cancer
【24h】

Interleukin-6 and interleukin-8 serum levels in prognosis of hormone- dependent breast cancer

机译：白细胞介素-6和白细胞介素-8血清水平在激素依赖性乳腺癌的预后

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Increasing amount of evidence points to the importance of immunity in breast cancer. The prognostic value of cytokines and their effect on tumorigenesis remains inconsistent. Aim: To investigate the prognostic significance of IL6 and IL8 and their association with ER and HER2 in estrogen-dependent (ER + ) breast cancer. Material and methods: The study included 79 premenopausal women with early and locally advanced ER+ breast cancer. All patients received adjuvant hormonal therapy: tamoxifen alone (56/79) or combination with LHRH agonist goserelin (23/79). IL6 and IL8 serum protein levels were measured by ELISA. Cox proportional hazards regression analysis was implemented for prognostic evaluation of the data categorized based on metastasis outcome. Results: IL6 associated with good (P = 0.001, HR = 0.05) and IL8 with poor disease outcome (P = 0.03, HR = 2.5) in the whole group of patients. Multivariate analyses highlighted IL6 as the independent prognostic factor (P = 0.001, HR = 0.0007). When patients were classified according to ER or HER2 status, IL6 did not have prognostic significance in ER~low and ER~hlgh subgroups, while IL8 retained prognostic significance only in the ER~high subgroup (P = 0.04, HR = 2.8). IL6 was significant in both HER2- (P = 0.001, HR = 0.05) and HER2 + subgroups (P = 0.002, HR = 0.04), while IL8 retained its prognostic significance only in the HER2 + subgroup (P = 0.001, HR = 77.8). Conclusions: This study contributes to the clarification of the prognostic performance of IL6 and IL8 by providing their first prognostic evaluation in the homogenized ER+ breast cancer patient group. IL6 was indicated as a marker of favorable, whereas IL8 was a marker of unfavorable disease outcome.
机译：背景：越来越多的证据表明乳腺癌免疫力的重要性。细胞因子的预后价值及其对肿瘤发生的影响仍然存在不一致。目的：探讨IL6和IL8的预后意义及其与ER和HER2在雌激素依赖性（ER +）乳腺癌中的关系。材料和方法：该研究包括79名患有早期和局部晚期ER +乳腺癌的前寄生妇女。所有患者均接受佐剂激素治疗：单独毒素（56/79）或与LHRH激动剂Goserelin组合（23/79）。通过ELISA测量IL6和IL8血清蛋白水平。基于转移结果分类的数据的预后评估实施了Cox比例危害回归分析。结果：IL6与良好（p = 0.001，hr = 0.05）和IL8相关的疾病结果差（p = 0.03，hr = 2.5）。多变量分析突出显示IL6作为独立预后因子（P = 0.001，HR = 0.0007）。当患者根据ER或HER2状态进行分类时，IL6在ER〜低和HLGH亚组中没有预后意义，而IL8仅在ER〜高亚组中保留了预后意义（P = 0.04，HR = 2.8）。 IL6在HER2-（P = 0.001，HR = 0.05）和HER2 +亚组中是显着的（p = 0.002，HR = 0.04），而IL8仅保留在HER2 +亚组中的预后意义（P = 0.001，HR = 77.8 ）。结论：本研究通过在均质ER +乳腺癌患者组中提供其首次预后评价，有助于澄清IL6和IL8的预后性能。 IL6表示为有利的标志物，而IL8是不利疾病结果的标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号